Skip to main content
SpringerLink
Log in

111In-Octreotide Infusions for the Treatment of Paraganglioma

  • Chapter
  • First Online:
Liver Intra-arterial PRRT with 111In-Octreotide

  • 227 Accesses

Abstract

Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic tool to confront neoplasms of neuroendocrine character both primaries and secondaries. Particularly, locoregional therapeutic schemes have been developed focused on the management of liver metastases. Among these novel therapeutic procedures, intra-arterial infusions of high doses of 111In-Octreotide were performed in our institution for more than a decade covering the whole spectrum of liver metastases both in early and in advanced cases. This chapter prescribes the Auger electron efficacy in paraganglioma primaries and liver-metastasized cases, as well.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–86.

    Article  Google Scholar 

  2. Hayashi T, Mete O. Head and neck paragangliomas: what does the pathologist need to know? Diagn Histopathol. 2014;20:316–25.

    Article  Google Scholar 

  3. Saveanu A, Muresan M, de Micco C, et al. Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18:287–300.

    Article  Google Scholar 

  4. Reubi JC, Waser B, Liu Q, Laissue JA, et al. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab. 2008;85:3882–91.

    Google Scholar 

  5. Binderup T, Knigge U, Mellon Mogensen A, et al. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008;87:223–32.

    Article  CAS  Google Scholar 

  6. Koopmans KP, Jager PL, Kema IP, et al. 111In-octreotide is superior to 123I-metaiodobenzylgianidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232–7.

    Article  Google Scholar 

  7. Charrier N, Deveze A, Fakhry N, et al. Comparison of [111In] pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol. 2011;74:21–9.

    Article  CAS  Google Scholar 

  8. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.

    Article  CAS  Google Scholar 

  9. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.

    Article  CAS  Google Scholar 

  10. Sajid MS, Hamilton G, Baker DM, Joint Vascular Research Group. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg. 2007;34:127–30.

    Article  CAS  Google Scholar 

  11. Chan JKC, Kimura N, Capella C, et al. Chapter 10: Paraganglion tumours. In: El-Nigger AK, Chan JKC, Grandis JF, Takata T, Slootweg PJ, editors. WHO classification of head and neck tumours. 4th ed. Lyon: IARC; 2017.

    Google Scholar 

  12. Blumenfeld J, Cohen N, Anwar M, et al. Hypertension and a tumor of the glomus jugular region. Evidence for epinephrine biosynthesis. Am J Hypertens. 1993;6:382–7.

    Article  CAS  Google Scholar 

  13. Piccini V, Rapizzi E, Bacca A, et al. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer. 2012;19:149–55.

    Article  CAS  Google Scholar 

  14. Lam KY, Lo CY, Wat NMS, et al. The clinicopathological features and importance of p53, Rb and mdm2 expression in pheochromocytomas and paragangliomas. J Clin Pathol. 2001;54:443–8.

    Article  CAS  Google Scholar 

  15. Lam KY, Chan ACL. Paraganglioma of urinary bladder: an immunohistochemical study and report of an unusual association with intestinal carcinoid. Aust N Z J Surg. 1993;63:740–5.

    Article  CAS  Google Scholar 

  16. Garg A, Mishra D, Bansal M, et al. Right atrial paraganglioma: an extremely rare primary cardiac neoplasm mimicking myxoma. J Cardiovasc Ultrasound. 2016;24:334–6.

    Article  Google Scholar 

  17. Michałowska I, Ćwikła J, Prejbisz A, et al. Mediastinal paragangliomas related to SDHx gene mutations. Kardiochir Torakochirurgia Pol. 2016;13:276–82.

    PubMed  PubMed Central  Google Scholar 

  18. Soomro NH, Zahid AB, Zafar AA. Non-functional paraganglioma of the mediastinum. J Pak Med Assoc. 2016;66:609–11.

    PubMed  Google Scholar 

  19. Blanchet EM, Martucci V, Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol. 2012;1:58.

    Article  Google Scholar 

  20. Assadipour Y, Sadowski SM, Alimchandani M, et al. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery. 2017;161:230–9.

    Article  Google Scholar 

  21. Coresmitt EP, Romijn JA. Clinical management of paragangliomas. Eur J Endocrinol. 2014;171(6):232–43.

    Google Scholar 

  22. Berends AMA, Buitenwerf E, de Krijger R, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med. 2018;51:68–73.

    Article  Google Scholar 

  23. Lenders JW, Duh QY, Eisenhofer G. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.

    Article  CAS  Google Scholar 

  24. Jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15:356–71.

    Article  Google Scholar 

  25. Fishbein L, Orlowski R, Cohen D. Pheochromocytoma/paraganglioma; review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma. J Clin Hypertens (Greenwich). 2013;15:428–34.

    Article  CAS  Google Scholar 

  26. Elston MS, Meyer-Rochow GY, et al. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas. Hum Pathol. 2015;46:390–6.

    Article  CAS  Google Scholar 

  27. Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab. 2017;32:152–61.

    Article  CAS  Google Scholar 

  28. van Essen M, Krenning EP, Kooij PP, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]-octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599–606.

    PubMed  Google Scholar 

  29. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90YDOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–23.

    Article  CAS  Google Scholar 

  30. Zovato S, Kumanova A, Demattè S, et al. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res. 2012;44(5):411–4.

    Article  CAS  Google Scholar 

  31. Cecchin D, Schiavi F, Fanti S, et al. Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas. J Clin Oncol. 2011;29(7):e171–4.

    Article  Google Scholar 

  32. Pinato DJ, Black JR, Ramaswami R, et al. Peptide receptor radionuclide therapy for metastatic paragangliomas. Med Oncol. 2016;33(5):47.

    Article  Google Scholar 

  33. Ashwathanarayana AG, Biswal CK, Sood A, et al. Imaging guided use of combined 177Lu-DOTATATE and capecitabine therapy in metastatic mediastinal paraganglioma. J Nucl Med Technol. 2017;45(4):314–6.

    Article  Google Scholar 

  34. Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab. 2017;102(9):3278–87.

    Article  Google Scholar 

  35. Nastos K, Cheung VT, Toumpanakis C, et al. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive pheochromocytomas and paragangliomas. J Surg Oncol. 2017;115(4):425–34.

    Article  CAS  Google Scholar 

  36. Garske-Román U, Sandström M, Fröss Baron K, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970–88.

    Article  Google Scholar 

  37. Yadav MP, Ballal S, Bal C. Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. EJNMMI Res. 2019;9:13. https://doi.org/10.1186/s13550-019-0484-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Vyakaranam AR, Crona J, Norlén O. Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE. Cancers. 2019;11(7):909. https://doi.org/10.3390/cancers11070909.

    Article  CAS  PubMed Central  Google Scholar 

  39. Kolasinska-Cwikła A, Peczkowska M, Cwikła JB. A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation. J Clin Med. 2019;8:952. https://doi.org/10.3390/jcm8070952www.mdpi.com/journal/jcm.

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece

    Georgios S. Limouris

  2. Nuclear Medicine Department, “A. Tsyb Research Center”, Obninsk, Russia

    Valery Krylov

  3. N.N. Blokhin Russian Oncological Research Center, Moscow, Russia

    Michael B. Dolgushin

  4. Nuclear Medicine Department, Army Share Fund Hospital of Athens, Athens, Greece

    Athanasios G. Zafeirakis

Authors
  1. Georgios S. Limouris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valery Krylov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael B. Dolgushin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Athanasios G. Zafeirakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgios S. Limouris .

Editor information

Editors and Affiliations

  1. Nuclear Medicine, Medical School National and Kapodistrian University of Athens, Athens, Greece

    Georgios S. Limouris

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Limouris, G.S., Krylov, V., Dolgushin, M.B., Zafeirakis, A.G. (2021). 111In-Octreotide Infusions for the Treatment of Paraganglioma. In: Limouris, G.S. (eds) Liver Intra-arterial PRRT with 111In-Octreotide. Springer, Cham. https://doi.org/10.1007/978-3-030-70773-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70773-6_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70772-9

  • Online ISBN: 978-3-030-70773-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation